"Our research findings reveal that Baxá protein levels are normally kept at essentially undetectable levels in healthy cells by the protein degradation machine in cells known as proteasomes," said Dr. Victor Yu, who led the Institute of Molecular and Cell Biology (IMCB) research team. ❋ Unknown (2009)
It is the specificity of the E3 enzyme that determines which proteins in the cell are to be marked for destruction in the proteasomes. ❋ Unknown (2004)
Proteins so labelled are then broken down degraded rapidly in cellular "waste disposers" called proteasomes. ❋ Unknown (2004)
A human cell contains about 30,000 proteasomes: these barrel-formed structures can break down practically all proteins to 7-9-amino-acid-long peptides. ❋ Unknown (2004)
The labelled proteins are then fed into the cells '"waste disposers", the so called proteasomes, where they are chopped into small pieces and destroyed. ❋ Unknown (2004)
The results showed that cells really break down faulty proteins using the ubiquitin system, and we now know that up to 30% of the newly-synthesised proteins in a cell are broken down via the proteasomes since they do not pass the cell's rigorous quality control. ❋ Unknown (2004)
Proteins so labelled are then rapidly broken down degraded in cellular "waste disposers" called proteasomes. ❋ Unknown (2004)
The new approaches are particularly attractive because the differences in assembly and gating mechanisms between human and TB proteasomes are more significant than the differences in the enzyme active sites that have been primary targets for drug development. ❋ Unknown (2010)
Seeger M, Janek K, Jungblut PR, Dahlmann B (2007) Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation. ❋ Michele Mishto Et Al. (2010)
Researchers have found that cancer cells are especially sensitive to proteasomes being blocked. ❋ Unknown (2010)
Moreover, when 20S proteasomes were inhibited by MG132 (final concentration of 5 µM) no substrate degradation was observed, confirming the absence of other proteases in the 20S proteasome preparation. ❋ Michele Mishto Et Al. (2010)
PA28-αβ and 20S proteasomes were purified from 9 LcLs (genotyped for LMP2 codon 60 polymorphism) as previously described ❋ Michele Mishto Et Al. (2010)
Higher-level organisms, such as humans or yeast, also have gate-closed proteasomes to degrade unwanted proteins. ❋ Unknown (2010)
Stohwasser R, Giesebrecht J, Kraft R, Muller EC, Hausler KG, et al. (2000) Biochemical analysis of proteasomes from mouse microglia: induction of immunoproteasomes by interferon-gamma and lipopolysaccharide. ❋ Michele Mishto Et Al. (2010)
Carfilzomib and ONX-0912 work to put a brake on proteasomes, enzymes that control the turnover of proteins in cells. ❋ Unknown (2010)
Schubert U, Antón LC, Gibbs J, Norbury CC, Yewdell JW, et al. (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. ❋ Virginie Renaud Et Al. (2010)
Furthermore it is clear that FOXL2 stability is not dependent on MG132 treatment, suggesting that FOXL2 degradation is not mediated by proteasomes. ❋ Mara Marongiu Et Al. (2010)
But in bacterial proteasomes, the seven end proteins are identical. ❋ Unknown (2010)
Thus, drugs designed to inactivate these aspects of the TB proteasome would be less likely to also inhibit proteasomes in human cells. ❋ Unknown (2010)
Bortezomib, an anticancer therapy approved to treat multiple myeloma and mantle cell lymphoma, normally fights disease by inhibiting proteasomes and inducing tumor cell death. ❋ Unknown (2009)
